Muscarinic antagonists in early stage clinical development for the treatment of asthma

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Parasympathetic neurons utilize the neurotransmitter acetylcholine to modulate and constrict airway smooth muscles at the muscarinic acetylcholine receptor. Inhaled agents that antagonize the muscarinic (M) acetylcholine receptor, particularly airway M3 receptors, have increasing data supporting use in persistent asthma. Areas covered: Use of inhaled long-acting muscarinic antagonists (LAMA) in asthma is explored. The LAMA tiotropium is approved for maintenance in symptomatic asthma patients despite the use of inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRA) and/or long-acting beta2 agonists (LABA). LAMA agents currently approved for chronic obstructive pulmonary disease (COPD) include tiotropium, glycopyrrolate/glycopyrronium, umeclidinium and aclidinium. These agents are reviewed for their pharmacological differences and clinical trials in asthma. Expert opinion: Current guidelines place inhaled LAMAs as adjunctive maintenance therapy in symptomatic asthma not controlled by an ICS and/or a LTRA. LAMA agents will play an increasing role in moderate to severe symptomatic asthma patients. Additional LAMA agents are likely to seek a maintenance indication perhaps as a combined inhaler with an ICS or with an ICS and a LABA. These fixed-dose combination inhalers are being tested in COPD and asthma patients. Once-a-day dosing of inhaled LAMA agents in severe asthma patients will likely become the future standard.

Original languageEnglish (US)
Pages (from-to)35-49
Number of pages15
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number1
DOIs
StatePublished - Jan 2 2017

Fingerprint

Muscarinic Antagonists
Asthma
Cholinergic Agents
Leukotriene Antagonists
Adrenal Cortex Hormones
Nebulizers and Vaporizers
Muscarinic Receptors
Therapeutics
Chronic Obstructive Pulmonary Disease
Glycopyrrolate
Maintenance
Steroid Receptors
Expert Testimony
Acetylcholine
Smooth Muscle
Neurotransmitter Agents
Clinical Trials
Pharmacology
Guidelines
Neurons

Keywords

  • aclidinium
  • Asthma
  • glycopyrrolate
  • long-acting muscarinic antagonist (LAMA)
  • tiotropium
  • umeclidinium

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{6fa636a09f3b4e07b480b419aef81b5f,
title = "Muscarinic antagonists in early stage clinical development for the treatment of asthma",
abstract = "Introduction: Parasympathetic neurons utilize the neurotransmitter acetylcholine to modulate and constrict airway smooth muscles at the muscarinic acetylcholine receptor. Inhaled agents that antagonize the muscarinic (M) acetylcholine receptor, particularly airway M3 receptors, have increasing data supporting use in persistent asthma. Areas covered: Use of inhaled long-acting muscarinic antagonists (LAMA) in asthma is explored. The LAMA tiotropium is approved for maintenance in symptomatic asthma patients despite the use of inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRA) and/or long-acting beta2 agonists (LABA). LAMA agents currently approved for chronic obstructive pulmonary disease (COPD) include tiotropium, glycopyrrolate/glycopyrronium, umeclidinium and aclidinium. These agents are reviewed for their pharmacological differences and clinical trials in asthma. Expert opinion: Current guidelines place inhaled LAMAs as adjunctive maintenance therapy in symptomatic asthma not controlled by an ICS and/or a LTRA. LAMA agents will play an increasing role in moderate to severe symptomatic asthma patients. Additional LAMA agents are likely to seek a maintenance indication perhaps as a combined inhaler with an ICS or with an ICS and a LABA. These fixed-dose combination inhalers are being tested in COPD and asthma patients. Once-a-day dosing of inhaled LAMA agents in severe asthma patients will likely become the future standard.",
keywords = "aclidinium, Asthma, glycopyrrolate, long-acting muscarinic antagonist (LAMA), tiotropium, umeclidinium",
author = "Albertson, {Timothy E} and James Chenoweth and Adams, {Jason Yeates} and Sutter, {Mark E}",
year = "2017",
month = "1",
day = "2",
doi = "10.1080/13543784.2017.1264388",
language = "English (US)",
volume = "26",
pages = "35--49",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Muscarinic antagonists in early stage clinical development for the treatment of asthma

AU - Albertson, Timothy E

AU - Chenoweth, James

AU - Adams, Jason Yeates

AU - Sutter, Mark E

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Introduction: Parasympathetic neurons utilize the neurotransmitter acetylcholine to modulate and constrict airway smooth muscles at the muscarinic acetylcholine receptor. Inhaled agents that antagonize the muscarinic (M) acetylcholine receptor, particularly airway M3 receptors, have increasing data supporting use in persistent asthma. Areas covered: Use of inhaled long-acting muscarinic antagonists (LAMA) in asthma is explored. The LAMA tiotropium is approved for maintenance in symptomatic asthma patients despite the use of inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRA) and/or long-acting beta2 agonists (LABA). LAMA agents currently approved for chronic obstructive pulmonary disease (COPD) include tiotropium, glycopyrrolate/glycopyrronium, umeclidinium and aclidinium. These agents are reviewed for their pharmacological differences and clinical trials in asthma. Expert opinion: Current guidelines place inhaled LAMAs as adjunctive maintenance therapy in symptomatic asthma not controlled by an ICS and/or a LTRA. LAMA agents will play an increasing role in moderate to severe symptomatic asthma patients. Additional LAMA agents are likely to seek a maintenance indication perhaps as a combined inhaler with an ICS or with an ICS and a LABA. These fixed-dose combination inhalers are being tested in COPD and asthma patients. Once-a-day dosing of inhaled LAMA agents in severe asthma patients will likely become the future standard.

AB - Introduction: Parasympathetic neurons utilize the neurotransmitter acetylcholine to modulate and constrict airway smooth muscles at the muscarinic acetylcholine receptor. Inhaled agents that antagonize the muscarinic (M) acetylcholine receptor, particularly airway M3 receptors, have increasing data supporting use in persistent asthma. Areas covered: Use of inhaled long-acting muscarinic antagonists (LAMA) in asthma is explored. The LAMA tiotropium is approved for maintenance in symptomatic asthma patients despite the use of inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRA) and/or long-acting beta2 agonists (LABA). LAMA agents currently approved for chronic obstructive pulmonary disease (COPD) include tiotropium, glycopyrrolate/glycopyrronium, umeclidinium and aclidinium. These agents are reviewed for their pharmacological differences and clinical trials in asthma. Expert opinion: Current guidelines place inhaled LAMAs as adjunctive maintenance therapy in symptomatic asthma not controlled by an ICS and/or a LTRA. LAMA agents will play an increasing role in moderate to severe symptomatic asthma patients. Additional LAMA agents are likely to seek a maintenance indication perhaps as a combined inhaler with an ICS or with an ICS and a LABA. These fixed-dose combination inhalers are being tested in COPD and asthma patients. Once-a-day dosing of inhaled LAMA agents in severe asthma patients will likely become the future standard.

KW - aclidinium

KW - Asthma

KW - glycopyrrolate

KW - long-acting muscarinic antagonist (LAMA)

KW - tiotropium

KW - umeclidinium

UR - http://www.scopus.com/inward/record.url?scp=85006792221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006792221&partnerID=8YFLogxK

U2 - 10.1080/13543784.2017.1264388

DO - 10.1080/13543784.2017.1264388

M3 - Review article

C2 - 27927039

AN - SCOPUS:85006792221

VL - 26

SP - 35

EP - 49

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 1

ER -